CereVasc
Manufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1st Avenue Building 39 100 Charlestown N...Phone Number
(617) 398-7067Website
www.cerevasc.comRevenue
$11.3 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About CereVasc
Located in Massachusetts healthcare hub, CereVasc, Inc. is a clinical-stage medical device company focused on developing novel, minimally invasive treatments for patients with neurological diseases. Its initial product, the eShunt System, employs an innovative percutaneous transvenous-transdural approach to the central nervous system and is intended to enable the first minimally invasive treatment for communicating hydrocephalus (CH). The patented eShunt System includes an endovascularly implantable cerebrospinal fluid shunt and delivery components designed to treat CH without invasive surgery.Explore more
CereVasc Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is CereVasc your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
CereVasc, which may be a good buyer, showed buying intent in Masked Content Topic
Check if CereVasc has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on CereVasc recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at CereVasc
Check out if CereVasc is spiking on competitors!
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when CereVasc launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if CereVasc had a recent Job posting/layoffs
Funding: Get notified immidiatlly once CereVasc has new funding data
Recommended Actions
Reach out to Masked Content who joined CereVasc as Masked Content
Find more new buyers
Compare Similar Companies to CereVasc
Compare insights from companies similar to CereVasc, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
CereVasc is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
CereVasc is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about CereVasc.
CereVasc financials insights
Gather financial insights about CereVasc, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$43.9M
2024
Series B
$70M
2026
Series C
$85M
CereVasc Tech Stack
A closer look at the technologies used by CereVasc
Most Recent Scoops
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Funding
Funding
Event
Events
CereVasc News & Media
CereVasc, Inc. Announces Over-Subscribed $85 Million Series C Financing to Advance its Novel eShunt® System for the Treatment of Normal Pressure Hydrocephalus
Financing led by Piper Sandler Merchant Banking, with participation from new investors Johnson & Johnson Innovation – JJDC, Inc., Johnson & Johnson's corporate venture capital arm, and Medtronic Participation by existing investors, including Bain Capital Life Sciences and Perceptive...First-in-Human Use of CereVasc® eShunt® System in Idiopathic Intracranial Hypertension Demonstrates Sustained Clinical Outcomes
Compassionate Use Case Reports Continued Symptom Improvement and Imaging-Confirmed Device Patency Through Three-Year Follow-Up BOSTON, March 4, 2026 /PRNewswire/ -- CereVasc, Inc., a clinical-stage medical device company developing novel minimally invasive treatments for neurological...CereVasc, Inc. Announces Publication of A Multi-Center Study Evaluating the eShunt® System in the Treatment of Patients with NPH
95% of Participants Demonstrated Clinical Improvement with No Device-Related Serious Adverse Events Through 90-Day Follow-Up BOSTON, Feb. 24, 2026 /PRNewswire/ -- CereVasc, Inc., a clinical-stage medical device company developing novel treatments for neurological diseases, today announced...CereVasc Completes Enrollment of ETCHES Study of the eShunt® System for the Treatment of Communicating Hydrocephalus
Landmark study demonstrates safety and performance of the eShunt System in the treatment of communicating hydrocephalus BOSTON, Jan. 21, 2026 /PRNewswire/ -- CereVasc, Inc., a clinical-stage medical device company developing novel, minimally invasive treatments for neurological diseases,...
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding CereVasc
Sign Up For FreeTo access detailed company insights
Located in Massachusetts healthcare hub, CereVasc, Inc. is a clinical-stage medical device company focused on developing novel, minimally invasive treatments for patients with neurological diseases. Its initial product, the eShunt System, employs an innovative percutaneous transvenous-transdural approach to the central nervous system and is intende... Read More
